Researchers have unveiled Cas12a2, a groundbreaking CRISPR technology that targets RNA to selectively destroy cancer and ...

UAB startup TIXiMED advances TIX100, a novel oral Type 1 diabetes therapy, into Phase 1b clinical testing. The ...

Summary: Researchers developed “Core2Edge,” an advanced ex vivo human tissue model that replicates the invasive spread and ...

ProtaGene is proud to announce that it has received Clinical Laboratory Improvement Amendments (CLIA) accreditation from the College of American Pathologists (CAP) for its Heidelberg site to perform ...

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor ...

Irvine-based biotech firm GlyTR Therapeutics advances pan-cancer therapy developed at UCI toward human trials through ProBio ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, ...

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Researchers at the ...

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs.

The newest anti-aging trend is unlike anything we've seen before. Here's what to know about treatments made from donated ...

A UAB study published in Immunity reveals that T cells help develop diverse anti-carbohydrate antibodies after early microbial exposure, offering new insights into immune defense, autoimmune disease, ...

Durham-based Humacyte, a regenerative medicine company, will soon begin a first-in-human clinical study of its bioengineered blood vessel in patients undergoing coronary artery bypass grafting (CABG).